3,093 Shares in Novo Nordisk A/S $NVO Purchased by Cypress Wealth Services LLC

Cypress Wealth Services LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,093 shares of the company’s stock, valued at approximately $213,000.

A number of other hedge funds have also bought and sold shares of NVO. Innova Wealth Partners bought a new position in Novo Nordisk A/S in the 2nd quarter valued at about $208,000. Sagespring Wealth Partners LLC increased its holdings in Novo Nordisk A/S by 6.3% in the 2nd quarter. Sagespring Wealth Partners LLC now owns 19,176 shares of the company’s stock valued at $1,324,000 after buying an additional 1,140 shares during the period. Boston Trust Walden Corp increased its holdings in Novo Nordisk A/S by 124.3% in the 2nd quarter. Boston Trust Walden Corp now owns 12,036 shares of the company’s stock valued at $831,000 after buying an additional 6,670 shares during the period. Frazier Financial Advisors LLC increased its holdings in Novo Nordisk A/S by 15.7% in the 2nd quarter. Frazier Financial Advisors LLC now owns 2,728 shares of the company’s stock valued at $188,000 after buying an additional 371 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its holdings in Novo Nordisk A/S by 9.0% in the 2nd quarter. Wilmington Savings Fund Society FSB now owns 18,895 shares of the company’s stock valued at $1,304,000 after buying an additional 1,562 shares during the period. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NVO has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Novo Nordisk A/S in a report on Tuesday. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and decreased their price target for the company from $59.00 to $47.00 in a report on Monday, September 29th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $76.00.

Novo Nordisk A/S Trading Down 1.4%

NVO opened at $56.67 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $119.09. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm has a market capitalization of $253.03 billion, a price-to-earnings ratio of 15.57, a PEG ratio of 2.60 and a beta of 0.68. The company’s 50 day moving average price is $55.80 and its two-hundred day moving average price is $62.98.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.